Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine

Mike Apley
Kansas State University

Changes in Food Animal Antibiotic Use

How the uses of antibiotics in food animals are authorized

Veterinary Authorization

- Veterinary Feed Directive (VFD) for all uses of medically important antibiotics in feed for food animals
 - No extralabel use allowed in major species
 - No use for growth promotion
 - Next step is critical evaluation of in-feed antibiotics with no specified duration of administration
- Prescription required for all water uses of medically important antibiotics
- Prescription required for majority of medically important antibiotics administered to individual animals
 - The rest are slated to be reviewed and added to prescription status (e.g., penicillin G, oxytetracycline, tylosin)

With the VFD and Prescription changes, veterinarians are not only going to be responsible for essentially all antimicrobial use in food animals...


They are going to be accountable.

A Veterinarian's VFD Checklist

- ✓ Do I have a valid VCPR to authorize this use?
- ✓ Is there a reason to use the product, or is it just habit?
- ✓ Is it legal?
- ✓ Is it effective?
- ✓ Are there any residue issues to consider?
- ✓ Are there any issues with antibiotic resistance?

FIGURE 2

ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS¹ ACTIVELY MARKETED IN 2015 SALES AND DISTRIBUTION DATA REPORTED BY DRUG CLASS



Domestic/Export³ and Drug Class

TABLE 3

ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS ACTIVELY MARKETED IN 2015 DOMESTIC SALES AND DISTRIBUTION DATA REPORTED BY MEDICAL IMPORTANCE AND DRUG CLASS

	Drug Class	Annual Totals (kg) ²	% Subtotal	% Grand Total
	Aminoglycosides ¹	344,120	4%	2%
	Amphenicols	44,968	<1%	<1%
	Cephalosporins ¹	32,341	<1%	<1%
	Fluoroquinolones	20,063	<1%	<1%
Medically Important ³	Lincosamides ¹	182,543	2%	1%
	Macrolides	627,770	6%	4%
	Penicillins ¹	936,669	10%	6%
	Sulfas	380,186	4%	2%
	Tetracyclines ¹	6,880,465	71%	44%
	NIR ^{1,5}	252,854	3%	2%
	Subtotal	9,701,978	100%	62%
Not Currently Medically Important	Ionophores	4,740,615	81%	30%
	NIR⁵	1,134,382	19%	7%
	Subtotal	5,874,997	100%	38%
	Grand Total	15,576,975		100%


TABLE 4

ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS ACTIVELY MARKETED IN 2015 DOMESTIC SALES AND DISTRIBUTION DATA REPORTED BY MEDICAL IMPORTANCE AND ROUTE OF ADMINISTRATION

	Route	Annual Totals (kg) ²	% Subtotal	% Grand Total
	Feed ^{<u>l</u>}	7,139,853	74%	46%
	Injection ¹	353,297	4%	2%
Medically Important ³	Intramammary	16,049	<1%	<1%
	Oral ^{<u>5</u>} or Topical <u></u> ¹	121,288	1%	1%
	Water [₫]	2,071,492	21%	13%
	Subtotal	9,701,978	100%	62%
Not Currently Medically Important ⁴	All Routes ⁷	5,874,997		38%
	Grand Total	15,576,975		100%

FIGURE 10

ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS¹ ACTIVELY MARKETED 2009-2015 DOMESTIC SALES AND DISTRIBUTION DATA REPORTED BY MEDICAL IMPORTANCE AND DRUG CLASS




Medical Importance and Drug Class

	Drug Class	2009 Annual Totals (kg) ²	2015 Annual Totals (kg) ²	% Change 2009 - 2015	% Change 2014 - 2015
	Aminoglycosides ^L	223,117	344,120	54%	13%
	Cephalosporins ¹	20,145	32,341	61%	2%
	Ionophores	3,739,352	4,740,615	27%	0%
	Lincosamides!	93,330	182,543	96%	-22%
Domestic	Macrolides ¹	562,062	627,770	12%	1%
	Penicillins <u>¹</u>	691,644	936,669	35%	6%
	Sulfas ^L	505,880	380,186	-25%	-16%
	Tetracyclines ¹	5,260,995	6,880,465	31%	4%
	NIR⁴⁴	1,490,932	1,452,267	-3%	-4%
	Subtotal	12,587,457	15,576,975	24%	1%
Export ³	NIRE ^{L2}	202,556	20,773	-90%	-32%
	Grand Total	12,790,013	15,597,749	22%	1%

FIGURE 11a

ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS ACTIVELY MARKETED 2009-2015 DOMESTIC SALES AND DISTRIBUTION DATA REPORTED BY MEDICAL IMPORTANCE AND ROUTE OF ADMINISTRATION



	Route	2009 Annual Totals (kg) ²	2015 Annual Totals (kg) ²	% Change 2009 - 2015	% Change 2014 - 2015
	Feed ^{<u>l</u>}	5,687,084	7,139,853	26%	2%
	Injection ¹	388,518	353,297	-9%	3%
<u>Medically</u> <u>Important³</u>	Intramammary	23,409	16,049	-31%	40%
	Oral ^{<u>l,5</u>} or Topical ^{<u>l,8</u>}	120,506	121,288	1%	17%
	Water ⁶	1,467,048	2,071,492	41%	1%
	Subtotal	7,686,564	9,701,978	26%	2%
Not Currently Medically Important ⁴	All Routes ^Z	4,900,893	5,874,997	20%	<1%
	Grand Total	12,587,457	15,576,975	24%	1%

Changes

- How the use of antibiotics in food animals are authorized
- Social media and marketing campaigns as drivers of public perception of antibiotic use in food animals

Drivers of Change in Food Animal Antimicrobial Use

California SB27

PARA - S621

DART - HR2459

Legislation

PAMTA – HR1552 ADUFA

Fluoroquinolones

VFD

Cephalosporins Regulation

AMDUCA

GFI 209 McDonald's

GFI 213 Chipotle

Tyson Retailation

Panera

Walmart Chic –Fil - A

The Overton Window

Unthinkable

Radical

Acceptable

Somic

Sensible

Popular

Policy

Prohibition of therapeutic uses of medically important antimicrobials

Prohibition of <u>prevention and</u> <u>control uses</u> of medically important antimicrobials

Prohibition of growth promotion uses of medically important antimicrobials

How to tell how long someone has been involved in the antibiotic resistance issue...

"If we just understood all of the data the way forward would be clear"


It is obvious that there are differing perceptions on how antibiotics fit in the grand scheme of treating infectious disease



Changes

- How the use of antibiotics in food animals are authorized
- Social media and marketing campaigns as drivers of public perception of antibiotic use in food animals
- New tools to evaluate the relationship between food animal antibiotic use and antibiotic resistance in human medicine


Is food animal use of antibiotics a contributor to resistance in human medicine?



RESISTANCE CHALLENGES IN HUMAN MEDICINE

Antibiotic-Resistant Microorganism	Infections Included	Infections not Included	Estimated Annual Number of Cases	Estimated Annual Number of Deaths
Carbapenem Resistant Enterobacteriaceae (CRE)	HAIs caused by <i>Klebsiella</i> and <i>E. coli</i> with onset in hospitalized patients	1, 2, 3	9,300	610
Drug-resistant <i>Neisseria</i> gonorrhoeae (any drug)	All infections		246,000	<5
Multidrug-resistant <i>Acinetobacter</i> (three or more drug classes)	HAIs with onset in hospitalized patients	1,2	7,300	500
Drug-resistant <i>Campylobacter</i> (azithromycin or ciprofloxacin)	All infections		310,000	28
Drug-resistant <i>Candida</i> (fluconazole)	HAIs with onset in hospitalized patients	1,2	3,400	220
Extended-spectrum β-Lactamase producing Enterobacteriaceae (ESBLs)	HAIs caused by <i>Klebsiella</i> and <i>E. coli</i> with onset in hospitalized patients	1,2,3	26,000	1700
Vancomycin-resistant <i>Enterococcus</i> (VRE)	HAIs with onset in hospitalized patients	1,2	20,000	1300
Multidrug-resistant <i>Pseudomonas</i> aeruginosa (three or more drug classes)	HAIs with onset in hospitalized patients	1,2	6,700	440
Drug-resistant non-typhoidal Salmonella (ceftriaxone, ciprofloxacin ⁷ , or 5 or more drug classes)	All infections		100,000	40

Antibiotic-Resistant Microorganism	Infections Included	Infections not Included	Estimated Annual Number of Cases	Estimated Annual Number of Deaths
Drug-resistant Salmonella Typhi (Ciprofloxacin ⁷)	All infections		3,800	<5
Drug-resistant <i>Shigella</i> (Azithromycin or ciprofloxacin)	All infections		27,000	<5
Methicillin-resistant Staphylococcus aureus (MRSA)	Invasive infections	4	80,000	11000
Streptococcus pneumoniae (full resistance to clinically relevant drugs)	All infections		1,200,000	7000
Drug-resistant tuberculosis (any clinically relevant drug)	All infections		1,042	50
Vancomycin-resistant Staphylococcus aureus (VRSA)	All infections		<5	<5
Erythromycin-resistant Group A Streptococcus	Invasive infections	5	1,300	160
Erythromycin-resistant Group B Streptococcus	Invasive infections	6	7,600	440
Summary Totals for Antibiotic-Resistant Infections			2,049,442	23,488
Clostridium difficile Infections	Healthcare-associated infections in acute care hospitals or in patients requiring hospitalization		250,000	14,000



Metrics?

Foodborne bacterial outbreaks
Resistance in these outbreaks
Illness, hospitalizations, deaths

Capable of quantitative risk assessment

Metrics?

"Reservoir of Resistance"

Non-foodborne exposure

Residue effect on gut microbiota

Maintenance and spread of resistance in the community

Not as well suited for risk assessment

Changes

- How the use of antibiotics in food animals are authorized
- Social media and marketing campaigns as drivers of public perception of antibiotic use in food animals
- New tools to evaluate the relationship between food animal antibiotic use and antibiotic resistance in human medicine
- An expectation of stewardship in the use of antibiotics in any species (including humans)

What is "Stewardship"?

1. Responsibility for appropriate diagnostics and establishment of an accurate and functional case definition

Enter..

5. Is this antibiotic intervention still necessary?

Yes...

2. Is there a non-antibiotic alternative which will appropriately prevent, control, or treat this disease challenge?

If not..

While asking...

While...

3. Selection of an antibiotic which has been demonstrated to be safe and effective for this purpose

4. Assuring use of the antibiotic as shown to be safe and effective

If we want to keep antibiotics

- Veterinarians should have control of all uses of antimicrobials in animals.
- Veterinarians and producers must practice true stewardship.
- Duration of therapy research is an absolute requirement.
- Continue the emphasis on prevention of infectious disease.
- Protocols and records!

Things that just aren't true

- "All pork-beef-chicken-turkey is antibiotic free because we observe slaughter withdrawal times."
- "Antibiotic resistance isn't an issue because they don't use oxytetracycline or chlortetracycline in human medicine."

The Building Blocks of Antibiotic Resistance

Antibiotic Exposure

Pathogen(s) Resistome

Resistance Transfer Pathogen(s)
Fitness

Resistance Fitness Cost

Environment Resistome

Microbiota Resistome

